Estimating the economic effect of harm associated with high risk prescribing of oral non-steroidal anti-inflammatory drugs in England: population based cohort and economic modelling study

被引:0
|
作者
Camacho, Elizabeth M. [1 ]
Penner, Leonie S. [1 ]
Taylor, Amy [2 ,3 ]
Guthrie, Bruce [4 ]
Avery, Anthony J. [2 ,3 ]
Ashcroft, Darren M. [3 ,5 ]
Morales, Daniel R. [6 ,7 ]
Rogers, Gabriel [1 ]
Chuter, Antony [1 ,3 ]
Elliott, Rachel A. [1 ,3 ]
机构
[1] Univ Manchester, Manchester Ctr Hlth Econ, Div Populat Hlth Hlth Serv Res & Primary Care, Manchester, England
[2] Univ Nottingham, Ctr Acad Primary Care, Sch Med, Nottingham, England
[3] NIHR Greater Manchester Patient Safety Res Collabo, Manchester, England
[4] Univ Edinburgh, Usher Inst, Adv Care Res Ctr, Edinburgh, Scotland
[5] Univ Manchester, Fac Biol Med & Hlth, Ctr Pharmacoepidemiol & Drug Safety, Sch Hlth Sci, Manchester, England
[6] Univ Dundee, Populat Hlth & Genom, Dundee DD1 4HN, Scotland
[7] Univ Southern Denmark, Dept Publ Hlth, Odense, Denmark
来源
BMJ-BRITISH MEDICAL JOURNAL | 2024年 / 386卷
基金
美国国家卫生研究院;
关键词
INFORMATION-TECHNOLOGY INTERVENTION; COST-EFFECTIVENESS; COMPLICATIONS; IMPACT; SAFETY; STRATEGIES; ARTHRITIS; ERRORS;
D O I
10.1136/bmj-2023-077880
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES To quantify prevalence, harms, and NHS costs in England of problematic oral non-steroidal antiinflammatory drug (NSAID) prescribing in high risk groups. DESIGN Population based cohort and economic modelling study. SETTING Economic models estimating patient harm associated with NSAID specific hazardous prescribing events, and cost to the English NHS, over a 10 year period, were combined with trends of hazardous prescribing event to estimate national levels of patient harm and NHS costs. PARTICIPANTS Eligible participants were prescribed oral NSAIDs and were in five high risk groups: older adults (>= 65 years) with no gastroprotection; people who concurrently took oral anticoagulants; or those with heart failure, chronic kidney disease, or a history of peptic ulcer. MAIN OUTCOME MEASURES Prevalence of hazardous prescribing events, by each event and overall, discounted quality adjusted life years (QALYs) lost, and cost to the NHS in England of managing harm. RESULTS QALY losses and cost increases were observed for each hazardous prescribing event (v no hazardous prescribing event). Mean QALYs per person were between 0.01 (95% credibility interval (CI) 0.01 to 0.02) lower with history of peptic ulcer, to 0.11 (0.04 to 0.19) lower with chronic kidney disease. Mean cost increases ranged from a non-statistically significant 14 pound (<euro>17; $18) (95% CI -71 pound to 98) pound in heart failure, to a statistically significant 1097 pound (236 pound to 2542) pound in people concurrently taking anticoagulants. Prevalence of hazardous prescribing events per 1000 patients ranged from 0.11 in people who have had a peptic ulcer to 1.70 in older adults. Nationally, the most common hazardous prescribing event (older adults with no gastroprotection) resulted in 1929 (1416 to 2452) QALYs lost, costing 2.46m pound (0.65m pound to 4.68m) pound. The greatest impact was in people concurrently taking oral anticoagulants: 2143 (894 to 4073) QALYs lost, costing 25.41m pound (5.25m pound to 60.01m) pound. Over 10 years, total QALYs lost were estimated to be 6335 (4471 to 8658) and an NHS cost for England of 31.43m pound (9.28m pound to 67.11m) pound. CONCLUSIONS NSAIDs continue to be a source of avoidable harm and healthcare cost in these five high risk populations, especially in inducing an acute event in people with chronic condition and people taking oral anticoagulants.
引用
收藏
页数:9
相关论文
共 24 条
  • [1] The Prevalence of High-Risk Prescribing of Oral Non-Steroidal Anti-Inflammatory Drugs in Primary Healthcare: A Single-Centre Retrospective Chart Review Study
    Assiri, Ghadah Asaad
    Alanazi, Bashayr Mohammed
    AlRuthia, Yazed
    HEALTHCARE, 2022, 10 (05)
  • [2] Risk of gastrointestinal bleeding associated with oral anticoagulation and non-steroidal anti-inflammatory drugs in patients with atrial fibrillation: a nationwide study
    Olsen, Anne-Marie Schjerning
    McGettigan, Patricia
    Gerds, Thomas Alexander
    Fosbol, Emil Loldrup
    Olesen, Jonas Bjerring
    Sindet-Pedersen, Caroline
    Staerk, Laila
    Hansen, Morten Lock
    Pallisgaard, Jannik Langtved
    Kober, Lars
    Torp-Pedersen, Christian
    Gislason, Gunnar Hilmar
    Lamberts, Morten
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2020, 6 (05) : 292 - 300
  • [3] Non-steroidal anti-inflammatory drugs and risk of cardiovascular disease in patients with rheumatoid arthritis: a nationwide cohort study
    Lindhardsen, Jesper
    Gislason, Gunnar Hilmar
    Jacobsen, Soren
    Ahlehoff, Ole
    Olsen, Anne-Marie Schjerning
    Madsen, Ole Rintek
    Torp-Pedersen, Christian
    Hansen, Peter Riis
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (08) : 1515 - 1521
  • [4] High-risk use of over-the-counter non-steroidal anti-inflammatory drugs: a population-based cross-sectional study
    Koffeman, Aafke R.
    Valkhoff, Vera E.
    Celik, Sevde
    't Jong, Geert W.
    Sturkenboom, Miriam C. J. M.
    Bindels, Patrick J. E.
    van der Lei, Johan
    Luijsterburg, Pim A. J.
    Bierma-Zeinstra, Sita M. A.
    BRITISH JOURNAL OF GENERAL PRACTICE, 2014, 64 (621) : E191 - E198
  • [5] Cardiovascular Risk with Non-Steroidal Anti-Inflammatory Drugs: Systematic Review of Population-Based Controlled Observational Studies
    McGettigan, Patricia
    Henry, David
    PLOS MEDICINE, 2011, 8 (09)
  • [6] Non-steroidal Anti-inflammatory Drugs may Worsen the Course of Community-Acquired Pneumonia: A Cohort Study
    Basille, Damien
    Plouvier, Nathalie
    Trouve, Charlotte
    Duhaut, Pierre
    Andrejak, Claire
    Jounieaux, Vincent
    LUNG, 2017, 195 (02) : 201 - 208
  • [7] Time-trends in the prescribing of gastroprotective agents to primary care patients initiating low-dose aspirin or non-steroidal anti-inflammatory drugs: a population-based cohort study
    Warle-van Herwaarden, Margaretha F.
    Koffeman, Aafke R.
    Valkhoff, Vera E.
    't Jong, Geert W.
    Kramers, Cornelis
    Sturkenboom, Miriam C.
    De Smet, Peter A. G. M.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 80 (03) : 589 - 598
  • [8] Cholinesterase inhibitors and non-steroidal anti-inflammatory drugs and the risk of peptic ulcers: A self-controlled study
    Szilcz, Mate
    Wastesson, Jonas W.
    Calderon-Larranaga, Amaia
    Prieto-Alhambra, Daniel
    Blotiere, Pierre-Olivier
    Maura, Geric
    Johnell, Kristina
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2024, 72 (02) : 456 - 466
  • [9] Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts
    Wong, Angel Y. S.
    MacKenna, Brian
    Morton, Caroline E.
    Schultze, Anna
    Walker, Alex J.
    Bhaskaran, Krishnan
    Brown, Jeremy P.
    Rentsch, Christopher T.
    Williamson, Elizabeth
    Drysdale, Henry
    Croker, Richard
    Bacon, Seb
    Hulme, William
    Bates, Chris
    Curtis, Helen J.
    Mehrkar, Amir
    Evans, David
    Inglesby, Peter
    Cockburn, Jonathan
    McDonald, Helen, I
    Tomlinson, Laurie
    Mathur, Rohini
    Wing, Kevin
    Forbes, Harriet
    Eggo, Rosalind M.
    Parry, John
    Hester, Frank
    Harper, Sam
    Evans, Stephen J. W.
    Smeeth, Liam
    Douglas, Ian J.
    Goldacre, Ben
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (07) : 943 - 951
  • [10] Non-Steroidal Anti-Inflammatory Drug Use and Risk of Anastomotic Leakage after Anterior Resection: A Protocol-Based Study
    Rutegard, Martin
    Westermark, Sofia
    Hultberg, Daniel Kverneng
    Haapamaki, Markku
    Matthiessen, Peter
    Rutegard, Jorgen
    DIGESTIVE SURGERY, 2016, 33 (02) : 129 - 135